200 related articles for article (PubMed ID: 33615933)
1. Immunotoxins and nanobody-based immunotoxins: review and update.
Khirehgesh MR; Sharifi J; Safari F; Akbari B
J Drug Target; 2021 Sep; 29(8):848-862. PubMed ID: 33615933
[TBL] [Abstract][Full Text] [Related]
2. Immunotoxins in cancer therapy: Review and update.
Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
[TBL] [Abstract][Full Text] [Related]
3. Production and Conjugation of Truncated Recombinant Diphtheria Toxin to VEGFR-2 Specific Nanobody and Evaluation of its Cytotoxic Effect on PC-3 Cell Line.
Shajari S; Farajollahi MM; Behdani M; Tarighi P
Mol Biotechnol; 2022 Nov; 64(11):1218-1226. PubMed ID: 35478310
[TBL] [Abstract][Full Text] [Related]
4. Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells.
Tang J; Li J; Zhu X; Yu Y; Chen D; Yuan L; Gu Z; Zhang X; Qi L; Gong Z; Jiang P; Yu J; Meng H; An G; Zheng H; Yang L
Oncotarget; 2016 Jun; 7(23):34070-83. PubMed ID: 27083001
[TBL] [Abstract][Full Text] [Related]
5. Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment.
Narbona J; Hernández-Baraza L; Gordo RG; Sanz L; Lacadena J
Biomolecules; 2023 Jun; 13(7):. PubMed ID: 37509078
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Immunotoxin Therapy of Solid Tumors: Challenges and Strategies.
Shan L; Liu Y; Wang P
J Basic Clin Med; 2013; 2(2):1-6. PubMed ID: 25309827
[TBL] [Abstract][Full Text] [Related]
7. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
Mathew M; Verma RS
Cancer Sci; 2009 Aug; 100(8):1359-65. PubMed ID: 19459847
[TBL] [Abstract][Full Text] [Related]
8. Immunotoxin treatment of cancer.
Pastan I; Hassan R; FitzGerald DJ; Kreitman RJ
Annu Rev Med; 2007; 58():221-37. PubMed ID: 17059365
[TBL] [Abstract][Full Text] [Related]
9. Radiolabeled nanobodies for tumor targeting: From bioengineering to imaging and therapy.
Piramoon M; Khodadust F; Hosseinimehr SJ
Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188529. PubMed ID: 33647388
[TBL] [Abstract][Full Text] [Related]
10. Novel therapy based on camelid nanobodies.
Unciti-Broceta JD; Del Castillo T; Soriano M; Magez S; Garcia-Salcedo JA
Ther Deliv; 2013 Oct; 4(10):1321-36. PubMed ID: 24116915
[TBL] [Abstract][Full Text] [Related]
11. Nanobodies and Cancer: Current Status and New Perspectives.
Allegra A; Innao V; Gerace D; Vaddinelli D; Allegra AG; Musolino C
Cancer Invest; 2018 Apr; 36(4):221-237. PubMed ID: 29658806
[TBL] [Abstract][Full Text] [Related]
12. Toxin-labeled monoclonal antibodies.
Kreitman RJ
Curr Pharm Biotechnol; 2001 Dec; 2(4):313-25. PubMed ID: 11762413
[TBL] [Abstract][Full Text] [Related]
13. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
Kreitman RJ
BioDrugs; 2009; 23(1):1-13. PubMed ID: 19344187
[TBL] [Abstract][Full Text] [Related]
14. EGFR and anti-EGFR nanobodies: review and update.
Sharifi J; Khirehgesh MR; Safari F; Akbari B
J Drug Target; 2021 Apr; 29(4):387-402. PubMed ID: 33210573
[TBL] [Abstract][Full Text] [Related]
15. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
Brinkmann U
In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
[TBL] [Abstract][Full Text] [Related]
16. Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer.
Weidle UH; Tiefenthaler G; Schiller C; Weiss EH; Georges G; Brinkmann U
Cancer Genomics Proteomics; 2014; 11(1):25-38. PubMed ID: 24633317
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of chimeric (human-murine) monoclonal antibody BR96 IgG, F(ab')2, and Fab' conjugated to Pseudomonas exotoxin.
Siegall CB; Gawlak SL; Chin JJ; Zoeckler ME; Kadow KF; Brown JP; Braslawsky GR
Bioconjug Chem; 1992; 3(4):302-7. PubMed ID: 1390985
[TBL] [Abstract][Full Text] [Related]
18. Generation of nanobodies targeting the human, transcobalamin-mediated vitamin B
Bloch JS; Sequeira JM; RamÃrez AS; Quadros EV; Locher KP
FASEB J; 2022 Apr; 36(4):e22222. PubMed ID: 35218573
[TBL] [Abstract][Full Text] [Related]
19. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
[TBL] [Abstract][Full Text] [Related]
20. Immunotoxins for targeted cancer therapy.
Pastan I; Kreitman RJ
Adv Drug Deliv Rev; 1998 Apr; 31(1-2):53-88. PubMed ID: 10837618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
